Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Jan 31, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-01-27

Reporting Person: Yorke Justin W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-27	Common Stock	S	1854	$3.30	Disposed	532563	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9323	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.37, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.